{
    "symbol": "AUGX",
    "quarter": 4,
    "year": 2022,
    "date": "2023-03-27 10:50:21",
    "content": " Total revenue for the fourth quarter was $8.8 million, representing a 33% year-over-year growth rate and we exited 2022 with $35 million in annual recurring revenue. As stated, revenue for the three months ended December 31, 2022 was $8.8 million, a 33% increase from the $6.6 million in the same period a year ago. Dollar-based net revenue retention for the fourth quarter of 2022 was 126% for our health enterprise customers, compared to 136% in the fourth quarter of 2021. Adjusted gross margin for the fourth quarter of 2022 was 46.5% and compares to 47.3% in the corresponding prior year period, and compares to 45.9% in the third quarter of 2022. Total operating expenses for the fourth quarter of 2022 were $9.5 million, increasing sequentially from $9.0 million in the third quarter of 2022. Non-GAAP operating expenses, which excludes stock-based compensation and one-time items grew 26%, compared to the fourth quarter of 2021, a deceleration from the 28% year-on-year in the third quarter. Adjusted EBITDA  driven by adding back depreciation, amortization, taxes, interest, one-time items and stock-based compensation to net loss was a loss of $4.2 million in the fourth quarter of 2022, compared to a loss of $3.7 million in the fourth quarter of 2021. Importantly, over the last two quarters, we have reduced our adjusted EBITDA operating losses by 20% or $1.1 million from $5.3 million in the second quarter of 2022 to $4.2 million in the fourth quarter. Due to strong finish to 2022 and a strong start to 2023, we are providing revenue guidance of approximately $42 million for the full-year of 2023, implying a 36% year-on-year growth rate."
}